DUBLIN, June 9, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs" report to their offering.

'Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs', discusses global commercial trends and prospects for human medicines applied in the veterinary setting, also called crossover drugs. A wide range of human drugs continue to be applied in the veterinary space due to a lack of approved animal therapies, convenience and the rising costs of veterinary research.

This new report provides insights into Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. Through a series of in-depth case studies this report provides insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and other insightful marketing information. Our new study also identifies and explores important drivers and restraints of the crossover drugs market.

A blockbuster drug in human health generates revenues in excess of $1 billion, whereas the animal health market's highest selling drugs achieve $50-100 million, with around 85% of animal sales reaching less than $1 million. In this way, many manufacturers of veterinary drugs are looking for products already licensed for human use to fill their pipelines.

Despite these drivers, there are safety, legal, ethical, and health issues associated with ELDU in animals. For instance, prescribing a human drug for veterinary use has its own risks. Mammalian species share many basic similarities in terms of responses to drugs, but there are differences seen at the cellular level, meaning responses may differ.

Another possibility might be that a human drug is prescribed despite the presence of a veterinary-approved alternative due to affordability issues, meaning a veterinarian could face legal issues.

This report provides details of Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. It includes insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and marketing information.

Scope

• What regulations need to be followed when prescribing human drugs off-label to pets and food-producing animals?
• What are the main factors driving the prescription of human medicines in animals?
• Marketed human drugs commonly used in companion animals
• - What are the differences in indication between the human and veterinary setting?
• - What are the dosage and side effects of those specific drugs in animals?
• - Are there any existing and approved veterinary therapies for the same indication? Why is the human drug preferred over the approved animal drug?
• - What are the key drivers and barriers that affect ELDU of human drugs in animals?
• - What is currently restricting the crossover drugs market?
• - What are the key animal health companies with prominent crossover drug portfolios?
• Explore recent financial performance, crossover drugs brands, and the number of species supported through their animal health product portfolio
• Identify emerging companies in the animal health market investigating and marketing crossover drugs

Key Topics Covered:

1. Introduction

2. The Human and Animal Healthcare Industries

3. Human Drugs for Veterinary Use: Overview Regulations for Human Drugs Applied in Veterinary Medicine

4. Regulation of Human Drugs for Veterinary Use in the US

5. Extra-Label Drug Use Algorithm

6. Regulation of Human Drugs for Veterinary Use in Canada

7. Regulation of Human Drugs for Veterinary Use in the EU Unmet Needs and Factors Promoting Demand for Human Drugs in the

8. Veterinary Space Human Drugs Applied in Veterinary Medicine: Case Studies

- Lysodren (Mitotane) in Dogs

- Fluoxetine hydrochloride (Prozac) in Dogs and Cats

- Benazepril (Lotensin, Fortekor) in Dogs and Cats

- Quinidine Sulfate in Horses and Dogs

9. Chemotherapy in Dogs and Cats Human Drugs for Veterinary Use: Key Marketed Products

- Sildenafil

- Methimazole

- Amlodipine

- Phenobarbital

- Levothyroxine

- Acetaminophen

- Hydroxyzine

- Humulin N

- Pentoxifylline

- Bethanechol

- Human Prescription and OTC Drugs used in Dogs and Cats Factors Driving the Crossover Drugs Market Factors Restraining the

10. Crossover Drugs Market Key Established Global Players in the Crossover Drugs Market

- Zoetis

- Boehringer Ingelheim Vetmedica

- Merck/MSD Animal Health

- Elanco (Eli Lilly)

- Merial (Sanofi)

- Bayer

For more information visit http://www.researchandmarkets.com/research/h95vm2/human_drugs_for

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets